Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial
Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR Jr, das Dores Cruz F, Gonçalves Brandão SM, Rigaud VOC, Higuchi-Dos-Santos MH, Hajjar LA, Kalil Filho R, Hoff PM, Sahade M, Ferrari MSM, de Paula Costa RL, Mano MS, Bittencourt Viana Cruz CB, Abduch MC, Lofrano Alves MS, Guimaraes GV, Issa VS, Bittencourt MS, Bocchi EA
J Am Coll Cardiol. 2018 May 22;71(20):2281-2290
CARDIONCOLOGY.ORG ABSTRACT:
The results from a randomized, double-blind, placebo-controlled to study the role of carvedilol in preventing ANT cardiotoxicity in 200 patients with HER2-negative breast cancer tumor status indicates that carvedilol had no impact on the incidence of early
onset of left ventricular ejection fraction reduction. However, the use of carvedilol resulted in a significant reduction in troponin levels and diastolic dysfunction.
© All Rights Reserved
Image source: https://link.springer.com/article/10.1007/s11936-019-0736-1